ADDITIONAL INFO

Stenabolic (SR‑9009) — Nuclear Receptor & Metabolic Signaling Research Compound

Stenabolic (SR‑9009) is a synthetic research compound that acts as an agonist of the nuclear receptors REV‑ERBα and REV‑ERBβ. Originally developed at The Scripps Research Institute under Professor Thomas Burris, it is used in laboratory studies to investigate circadian rhythm regulation, metabolic signaling, energy balance pathways, and related cellular mechanisms.

For in‑vitro laboratory research only. Not a drug, food, cosmetic, or veterinary product. Not for human or animal administration.

Product Details

Compound Name: Stenabolic (SR‑9009)
Net Contents: Oral 20mg capsules
Purity: ≥98% (HPLC tested; Certificate of Analysis available)
Primary Targets: REV‑ERBα and REV‑ERBβ nuclear receptors, circadian and metabolic pathways
Manufactured in: GMP-compliant facility
Intended Use: Laboratory research use only — not for human or veterinary use

Storage & Handling

• Store sealed at −20 °C, protected from light and moisture

• Short-term storage: 2–8 °C in sealed vials

• Allow vial to reach room temperature before opening

• Reconstitute under sterile conditions using appropriate buffers

• Avoid repeated freeze–thaw cycles

• Consult SDS for safety and handling guidance

Research Applications

Stenabolic (SR‑9009) is commonly used in laboratory and preclinical studies to investigate:

• Circadian rhythm regulation and REV‑ERB receptor activity

• Metabolic signaling and energy balance pathways

• Lipid and glucose metabolism in experimental models

• Mitochondrial function and cellular bioenergetics

• Preclinical studies of circadian-mediated transcriptional networks